Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 15, 2015 - Issue 6
Submit an article Journal homepage
939
Views
45
CrossRef citations to date
0
Altmetric
Reviews

Estimating the direct and indirect costs associated with Parkinson’s disease

Carmen Rodríguez-BlázquezNational Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, SpainCorrespondence[email protected]
,
Maria João ForjazNational School of Public Health and REDISSEC, Carlos III Institute of Health, Madrid, Spain
,
Luis LizánOutcomes’10, Castellón de la Plana, Spain
,
Silvia PazOutcomes’10, Castellón de la Plana, Spain
&
Pablo Martínez-MartínNational Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain
Pages 889-911 | Published online: 29 Oct 2015

References

  • Papers of special note have been highlighted as:
  • *of interest
  • **of considerable interest
  • Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376.
  • De Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–535.
  • Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. Jama. 2014;311(16):1670–1683.
  • Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386.
  • Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson’s disease: impact of motor fluctuations and dyskinesias. PharmacoEconomics. 2001;19(10):1013–1038.
  • Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ. Quality of life and burden in caregivers for patients with Parkinson’s disease: concepts, assessment and related factors. Expert Rev Pharmacoecon Outcomes Res. 2012;12(2):221–230.
  • Martinez-Martin P, Arroyo S, Rojo-Abuin JM, et al. Burden, perceived health status, and mood among caregivers of Parkinson’s disease patients. Mov Disord. 2008;23(12):1673–1680.
  • Carod-Artal FJ, Mesquita HM, Ziomkowski S, et al. Burden and health-related quality of life among caregivers of Brazilian Parkinson’s disease patients. Parkinsonism Relat Disord. 2013;19(11):943–948.
  • Rice DP. Cost of illness studies: what is good about them?. Inj Prev. 2000;6(3):177–179.
  • O’Brien JA, Ward A, Michels SL, et al. Economic burden associated with Parkinson disease in the United States. Drug Benefit Trends. 2009;21(6):179–190.
  • Mateus C, Coloma J. Health Economics and cost of illness in Parkinson’s disease. Eur Neurol Rev. 2013;8(1):6–9.
  • Winter Y, Balzer-Geldsetzer M, Von Campenhausen S, et al. Trends in resource utilization for Parkinson’s disease in Germany. J Neurol Sci. 2010;294(1–2):18–22.
  • Dodel R, Jönsson B, Reese JP, et al. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson’s disease. Mov Disord. 2014;29(2):169–176.

** Essential and useful review, promoted by the Movement Disorders Society, of scales for outcomes assessment in economic studies in Parkinson’s disease.

  • Rubenstein LM, DeLeo A, Chrischilles EA. Economic and health-related quality of life considerations of new therapies in Parkinson’s disease. PharmacoEconomics. 2001;19(7):729–752.
  • Chen JJ. Parkinson’s disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care. 2010;16:S87–93.Suppl Implications.
  • Cubo E. Pharmacotherapy in the management of early Parkinson’s disease: cost-effectiveness and patient acceptability. Clin Outcomes Res. 2010;2:127–134.
  • Reese JP, Dams J, Winter Y, et al. Pharmacoeconomic considerations of treating patients with advanced Parkinson’s disease. Expert Opin Pharmacother. 2012;13(7):939–958.

** In-depth revision on the economic impact of treatments for advanced Parkinson’s disease.

  • Dams J, Bornschein B, Reese JP, et al. Modelling the cost effectiveness of treatments for Parkinson’s disease: a methodological review. PharmacoEconomics. 2011;29(12):1025–1049.
  • Shearer J, Green C, Counsell CE, et al. The use of decision-analytic models in Parkinson’s disease: a systematic review and critical appraisal. Appl Health Econ Health Policy. 2011;9(4):243–258.
  • Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson’s disease. Mov Disord. 2005;20(11):1449–1454.
  • Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson’s disease in Germany. PharmacoEconomics. 2005;23(8):817–836.
  • Péchevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005;12(12):956–963.
  • Cordato DJ, Schwartz R, Abbott E, et al. A comparison of health-care costs involved in treating people with and without Parkinson’s disease in Southern Sydney, New South Wales, Australia. J Clin Neurosci. 2006;13(6):655–658.
  • Leibson CL, Long KH, Maraganore DM, et al. Direct medical costs associated with Parkinson’s disease: a population-based study. Mov Disord. 2006;21(11):1864–1871.
  • Noyes K, Liu H, Li Y, et al. Economic burden associated with Parkinson’s disease on elderly Medicare beneficiaries. Mov Disord. 2006;21(3):362–372.
  • Ragothaman M, Govindappa ST, Rattihalli R, et al. Direct costs of managing Parkinson’s disease in India: concerns in a developing country. Mov Disord. 2006;21(10):1755–1758.
  • Schoenen J, Gianni F, Schretlen L, et al. Cost estimates of brain disorders in Belgium. Acta Neurol Belg. 2006;106(4):208–214.

* Comparative study on the cost of illness of Parkinson’s disease in six European countries from a societal point of view.

  • Vossius C, Gjerstad M, Baas H, et al. Drug costs for patients with Parkinson’s disease in two different European countries. Acta Neurol Scand. 2006;113(4):228–232.
  • Wang G, Cheng Q, Zheng R, et al. Economic burden of Parkinson’s disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov Disord. 2006;21(9):1439–1443.
  • Noyes K, Liu H, Temkin-Greener H. Cost of caring for Medicare beneficiaries with Parkinson’s disease: impact of the CMS-HCC risk-adjustment model. Dis Manag. 2006;9(6):339–348.
  • Abasolo-Osinaga E, Abecia-Inchaurregui LC, Fernández-Díaz E, et al. The prevalence and pharmacological cost of Parkinson’s disease in Spain. Rev Neurol. 2006;43(11):641–645.
  • McCrone P, Allcock LM, Burn DJ. Predicting the cost of Parkinson’s disease. Mov Disord. 2007;22(6):804–812.
  • Cubo E, Martínez Martin P, González M, et al. miembros del grupo ELEP. Impact of motor and non-motor symptoms on the direct costs of Parkinson’s disease. Neurol Barc Spain. 2008;24(1):15–23.
  • Sillanpää M, Andlin-Sobocki P, Lönnqvist J. Costs of brain disorders in Finland. Acta Neurol Scand. 2008;117(3):167–172.
  • McCrone P. Capturing the costs of end-of-life care: comparisons of multiple sclerosis, Parkinson’s disease, and dementia. J Pain Symptom Manage. 2009;38(1):62–67.
  • Vossius C, Nilsen OB, Larsen JP. Parkinson’s disease and nursing home placement: the economic impact of the need for care. Eur J Neurol. 2009;16(2):194–200.
  • Winter Y, Balzer-Geldsetzer M, Spottke A, et al. Longitudinal study of the socioeconomic burden of Parkinson’s disease in Germany. Eur J Neurol. 2010;17(9):1156–1163.
  • Winter Y, Von Campenhausen S, Brozova H, et al. Costs of Parkinson’s disease in eastern Europe: a Czech cohort study. Parkinsonism Relat Disord. 2010;16(1):51–56.

* This is the only study to date on the economic impact of slowing progression of Parkinson’s disease.

  • Winter Y, Von Campenhausen S, Reese JP, et al. Costs of Parkinson’s disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Neurodegener Dis. 2010;7(6):365–372.
  • Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson’s disease: evidence from administrative claims data. Mov Disord. 2010;25(4):474–480.
  • Reese JP, Winter Y, Rosa MM, et al. Health-economic burden of Parkinson’s disease in Portugal: a cohort study. Rev Neurol. 2011;52(5):264–274.
  • Von Campenhausen S, Winter Y, Rodrigues E Silva A, et al. Costs of illness and care in Parkinson’s disease: an evaluation in six countries. Eur Neuropsychopharmacol. 2011;21(2):180–191.
  • Zhao YJ, Tan LCS, Li SC, et al. Economic burden of Parkinson’s disease in Singapore. Eur J Neurol. 2011;18(3):519–526.
  • Vossius C, Larsen JP, Janvin C, et al. The economic impact of cognitive impairment in Parkinson’s disease. Mov Disord. 2011;26(8):1541–1544.
  • Findley LJ, Wood E, Lowin J, et al. The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset. J Med Econ. 2011;14(1):130–139.
  • Jennum P, Zoetmulder M, Korbo L, et al. The health-related, social, and economic consequences of parkinsonism: a controlled national study. J Neurol. 2011;258(8):1497–1506.
  • Johnson S, Davis M, Kaltenboeck A, et al. Early retirement and income loss in patients with early and advanced Parkinson’s disease. Appl Health Econ Health Policy. 2011;9(6):367–376.
  • McClelland S. A cost analysis of intraoperative microelectrode recording during subthalamic stimulation for Parkinson’s disease. Mov Disord. 2011;26(8):1422–1427.

* Cost-effectiveness analysis of the most recent treatments for advanced Parkinson’s disease: apomorphine injections, levodopa/carbidopa intestinal gel and deep brain stimulation, in two European countries.

  • Bach J-P, Riedel O, Klotsche J, et al. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson’s disease. J Neurol Sci. 2012;314(1–2):41–47.
  • Kaltenboeck A, Johnson SJ, Davis MR, et al. Direct costs and survival of medicare beneficiaries with early and advanced Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(4):321–326.
  • Lökk J, Borg S, Svensson J, et al. Drug and treatment costs in Parkinson’s disease patients in Sweden. Acta Neurol Scand. 2012;125(2):142–147.
  • CDBE2010 study group, Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–162.
  • Suh D-C, Pahwa R, Mallya U. Treatment patterns and associated costs with Parkinson’s disease levodopa induced dyskinesia. J Neurol Sci. 2012;319(1–2):24–31.
  • Johnson SJ, Kaltenboeck A, Diener M, et al. Costs of Parkinson’s disease in a privately insured population. PharmacoEconomics. 2013;31(9):799–806.
  • Kowal SL, Dall TM, Chakrabarti R, et al. The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord. 2013;28(3):311–318.
  • Richy FF, Pietri G, Moran KA, et al. Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson’s disease: a retrospective claims database analysis. Appl Health Econ Health Policy. 2013;11(4):395–406.
  • Zhao YJ, Tan LCS, Au WL, et al. Estimating the lifetime economic burden of Parkinson’s disease in Singapore. Eur J Neurol. 2013;20(2):368–374.
  • Valldeoriola F, Puig-Junoy J, Puig-Peiró R. Workgroup of the SCOPE study. Cost analysis of the treatments for patients with advanced Parkinson’s disease: SCOPE study. J Med Econ. 2013;16(2):191–201.
  • Tamás G, Gulácsi L, Bereczki D, et al. Quality of life and costs in Parkinson’s disease: a cross sectional study in Hungary. PloS One. 2014;9(9):e107704.
  • Low V, Ben-Shlomo Y, Coward E, et al. Measuring the burden and mortality of hospitalisation in Parkinson’s disease: a cross-sectional analysis of the English Hospital Episodes Statistics Database 2009-2013. Parkinsonism Relat Disord. 2015;21(5):449–454.
  • Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson’s disease patients with wearing-off. Curr Med Res Opin. 2005;21(7):1005–1014.
  • Noyes K, Dick AW, Holloway RG. Parkinson Study Group. Pramipexole and levodopa in early Parkinson’s disease: dynamic changes in cost effectiveness. PharmacoEconomics. 2005;23(12):1257–1270.
  • Lundqvist C, Beiske AG, Reiertsen O, et al. Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients. J Neurol. 2014;261(12):2438–2445.
  • Gage H, Kaye J, Owen C, et al. Evaluating rehabilitation using cost-consequences analysis: an example in Parkinson’s disease. Clin Rehabil. 2006;20(3):232–238.
  • Hudry J, Rinne JO, Keränen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkinson’s disease in Finland. Ann Pharmacother. 2006;40(4):651–657.
  • Fraix V, Houeto J-L, Lagrange C, et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77(4):443–449.
  • Valldeoriola F, Morsi O, Tolosa E, et al. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson’s disease. Mov Disord. 2007;22(15):2183–2191.
  • Antonini A, Berto P, Lopatriello S, et al. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson’s disease in Italy. Mov Disord. 2008;23(15):2202–2209.
  • Haycox A, Armand C, Murteira S, et al. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson’s disease in the UK setting: an economic Markov model evaluation. Drugs Aging. 2009;26(9):791–801.
  • Kristiansen IS, Bingefors K, Nyholm D, et al. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden: an exploratory study. Appl Health Econ Health Policy. 2009;7(3):167–180.
  • Munneke M, Nijkrake MJ, Keus SH, et al. Efficacy of community-based physiotherapy networks for patients with Parkinson’s disease: a cluster-randomised trial. Lancet Neurol. 2010;9(1):46–54.

** Remarkable study focused exclusively on the indirect costs of Parkinson’s disease.

  • Groenendaal H, Tarrants ML, Armand C. Treatment of advanced Parkinson’s disease in the United States: a cost-utility model. Clin Drug Investig. 2010;30(11):789–798.
  • Lowin J, Bergman A, Chaudhuri KR, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK. J Med Econ. 2011;14(5):584–593.
  • Fletcher E, Goodwin VA, Richards SH, et al. An exercise intervention to prevent falls in Parkinson’s: an economic evaluation. BMC Health Serv Res. 2012;12:426.
  • Weaver FM, Stroupe KT, Cao L, et al. Parkinson’s disease medication use and costs following deep brain stimulation. Mov Disord. 2012;27(11):1398–1403.
  • Farkouh RA, Wilson MR, Tarrants ML, et al. Cost-effectiveness of rasagiline compared with first-line early Parkinson disease therapies. Am J Pharm Benefits. 2012;4(3):99–107.
  • Dams J, Siebert U, Bornschein B, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson’s disease. Mov Disord. 2013;28(6):763–771.
  • Johnson SJ, Diener MD, Kaltenboeck A, et al. An economic model of Parkinson’s disease: implications for slowing progression in the United States. Mov Disord. 2013;28(3):319–326.
  • Kamusheva MS, Gerasimov N, Petrova GI. Intestinal gel Levodopa + Carbidopa in Parkinson’s patients with frequent and prolonged akinesia - an economic evaluation. Int J Pharm Sci Rev Res. 2013;22(1):244–246.
  • Eggington S, Valldeoriola F, Chaudhuri KR, et al. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson’s disease. J Neurol. 2014;261(1):106–116.
  • Stroupe KT, Weaver FM, Cao L, et al. Cost of deep brain stimulation for the treatment of Parkinson’s disease by surgical stimulation sites. Mov Disord. 2014;29(13):1666–1674.
  • Zhu XL, Chan DTM, Lau CKY, et al. Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study. World Neurosurg. 2014;82(6):987–993.
  • Van Boven JFM, Novak A, Driessen MT, et al. Economic evaluation of ropinirole prolonged release for treatment of Parkinson’s disease in the Netherlands. Drugs Aging. 2014;31(3):193–201.
  • Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany. J Med Econ. 2015;18(2):155–165.
  • Sturkenboom IHWM, Hendriks JCM, Graff MJL, et al. Economic evaluation of occupational therapy in Parkinson’s disease: A randomized controlled trial. Mov Disord. 2015;30(8):1059–1067.
  • Eggert KM, Reese JP, Oertel WH, et al. Cost effectiveness of pharmacotherapies in early Parkinson’s disease. CNS Drugs. 2008;22(10):841–860.
  • Meissner W, Schreiter D, Volkmann J, et al. Deep brain stimulation in late stage Parkinson’s disease: a retrospective cost analysis in Germany. J Neurol. 2005;252(2):218–223.
  • Hurwitz B, Jarman B, Cook A, et al. Scientific evaluation of community-based Parkinson’s disease nurse specialists on patient outcomes and health care costs. J Eval Clin Pract. 2005;11(2):97–110.
  • Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging. 2006;23(9):693–721.
  • Winter Y, Von Campenhausen S, Popov G, et al. Costs of illness in a Russian cohort of patients with Parkinson’s disease. Pharmaco Econ. 2009;27(7):571–584.
  • Bach J-P, Ziegler U, Deuschl G, et al. Projected numbers of people with movement disorders in the years 2030 and 2050. Mov Disord. 2011;26(12):2286–2290.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.